Mainz Biomed (NASDAQ: MYNZ) grants director 45,000 Ordinary Shares

Rhea-AI Filing Summary

Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.

Mainz Biomed N.V. director Heinrich Dreismann was granted 45,000 Ordinary Shares on February 13, 2026. The shares were issued as a grant under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, and the footnotes state that no cash consideration was paid for this award.

Following this equity grant, Dreismann directly owns 64,700 Ordinary Shares. A separate footnote notes that 19,700 employee stock options were previously granted and reported on a Form 3 filed on January 26, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dreismann Heinrich

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	45,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 64,700 shares (Direct)

Footnotes (1)

1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dreismann Heinrich

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ 55129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/13/2026		A		45,000	A	$0(1)	64,700(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.

2. 19,700 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

	/s/ Heiner Dreismann	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mainz Biomed (MYNZ) report in this Form 4 filing?

Mainz Biomed reported that director Heinrich Dreismann received a grant of 45,000 Ordinary Shares. The grant came under the company’s 2025 Omnibus Incentive Plan and involved no cash payment, reflecting equity-based compensation rather than an open-market transaction.

How many Mainz Biomed (MYNZ) shares does Heinrich Dreismann own after the grant?

After the reported grant, Heinrich Dreismann directly owns 64,700 Ordinary Shares of Mainz Biomed. This total reflects the addition of 45,000 granted shares to his prior holdings, as disclosed in the Form 4 insider transaction report.

Was cash paid for the 45,000-share grant reported by Mainz Biomed (MYNZ)?

No cash was paid for the 45,000-share grant. A footnote explains the Ordinary Shares were granted as restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, making this a non-cash equity compensation award rather than a purchase for cash.

What is the significance of the 19,700 Mainz Biomed (MYNZ) stock options mentioned?

The filing notes that 19,700 employee stock options were previously granted to Heinrich Dreismann and already reported on a Form 3 filed on January 26, 2026. This clarifies those options are not part of the newly reported 45,000-share grant.

Is the Mainz Biomed (MYNZ) Form 4 transaction a buy or a grant?

The Form 4 transaction is a grant/award acquisition, not an open-market buy. The transaction code is “A” for grant or award, and the footnote confirms the 45,000 Ordinary Shares were granted under the 2025 Omnibus Incentive Plan without cash consideration.